These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23252194)

  • 1. Antiviral agents and hepatitis C.
    Archer-Festa M; Nilsen-Kupsch S
    N Y State Dent J; 2012; 78(4):42-5. PubMed ID: 23252194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct-acting antiviral (DAA) actions in treatment-naïve patients.
    Hézode C
    Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S52-8. PubMed ID: 22248695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protease inhibitors in hepatitis C: from chronic disease to cure.
    Iqbal M; McCormick PA
    Ir Med J; 2011 Sep; 104(8):230-1. PubMed ID: 22125874
    [No Abstract]   [Full Text] [Related]  

  • 4. [Future of antiviral therapy for chronic hepatitis C. Direct antiviral acting medications].
    Lange CM; Sarrazin C; Zeuzem S
    Pharm Unserer Zeit; 2011 Jan; 40(1):60-7. PubMed ID: 21194084
    [No Abstract]   [Full Text] [Related]  

  • 5. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.
    Jacobson IM; Pawlotsky JM; Afdhal NH; Dusheiko GM; Forns X; Jensen DM; Poordad F; Schulz J
    J Viral Hepat; 2012 May; 19 Suppl 2():1-26. PubMed ID: 22404758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A new era in therapy of hepatitis C: "the therapy can now be individualized" (interview by Dr. med. Dirk Einecke)].
    Manns M
    MMW Fortschr Med; 2011 Jul; 153(29-31):17. PubMed ID: 21830729
    [No Abstract]   [Full Text] [Related]  

  • 7. Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections.
    Venkatraman S
    Trends Pharmacol Sci; 2012 May; 33(5):289-94. PubMed ID: 22521415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of hepatitis C: new inhibitors as hammers against HCV].
    Bublak R
    MMW Fortschr Med; 2013 Jun; 155 Suppl 1():10-1. PubMed ID: 23961643
    [No Abstract]   [Full Text] [Related]  

  • 9. New developments in HCV therapy.
    Kronenberger B; Zeuzem S
    J Viral Hepat; 2012 Jan; 19 Suppl 1():48-51. PubMed ID: 22233414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the use of direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection.
    Fernández-Yunquera A; Rincón D; Salcedo M; Bañares R
    Rev Esp Quimioter; 2013 Sep; 26(3):189-92. PubMed ID: 24080883
    [No Abstract]   [Full Text] [Related]  

  • 11. [New times for the treatment of chronic hepatitis C].
    Gerstoft J; Fomsgaard A
    Ugeskr Laeger; 2012 Mar; 174(12):795. PubMed ID: 22433552
    [No Abstract]   [Full Text] [Related]  

  • 12. Future of hepatitis C therapy: development of direct-acting antivirals.
    Dore GJ; Matthews GV; Rockstroh J
    Curr Opin HIV AIDS; 2011 Nov; 6(6):508-13. PubMed ID: 21897228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of boceprevir: a first-in-class direct antiviral treatment for chronic hepatitis C infection.
    Hazuda DJ; Burroughs M; Howe AY; Wahl J; Venkatraman S
    Ann N Y Acad Sci; 2013 Jul; 1291():69-76. PubMed ID: 23859802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral hepatitis C in 2014--the beginning of the end?
    Prelipcean CC; Gogălniceanu P; Mihai C
    Rev Med Chir Soc Med Nat Iasi; 2014; 118(2):272-8. PubMed ID: 25076687
    [No Abstract]   [Full Text] [Related]  

  • 15. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.
    Welsch C; Jesudian A; Zeuzem S; Jacobson I
    Gut; 2012 May; 61 Suppl 1():i36-46. PubMed ID: 22504918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infectious diseases. First specific drugs raise hopes for hepatitis C.
    Enserink M
    Science; 2011 Apr; 332(6026):159-60. PubMed ID: 21474720
    [No Abstract]   [Full Text] [Related]  

  • 17. Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.
    Trembling PM; Tanwar S; Dusheiko GM
    Expert Rev Anti Infect Ther; 2012 Mar; 10(3):269-79. PubMed ID: 22397560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telaprevir and boceprevir: a potential role for therapeutic drug monitoring.
    Dolton MJ; Ray JE; McLachlan AJ
    Ther Drug Monit; 2013 Jun; 35(3):414-5. PubMed ID: 23670484
    [No Abstract]   [Full Text] [Related]  

  • 19. [Antiviral treatment of chronic hepatitis C].
    Berger A
    Med Monatsschr Pharm; 2012 Feb; 35(2):55-60. PubMed ID: 22400430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively].
    Kozielewicz D; Halota W; Dybowska D
    Przegl Epidemiol; 2012; 66(1):49-54. PubMed ID: 22708298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.